PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Wilhelm, A.D.* ; Flynn, C.* ; Hammer, E.* ; Rössler, J. ; Haller, B.* ; Napieralski, R.* ; Leuthner, M.* ; Tosheska, S.* ; Knoops, K.* ; Mathew, A.* ; Ciarimboli, G.* ; Kranich, J.* ; Flaskamp, L.* ; King, S.* ; Gevensleben, H.* ; Emslander, Q.* ; Pastucha, A.* ; Reisbeck, M.* ; Rief, L.* ; Bronger, H.* ; Dreyer, T.* ; Bausch, A.R.* ; Pichlmair, A.* ; Brocker, T.* ; Zeidler, R. ; Hammerschmidt, W. ; Piedavent-Salomom, M.* ; López-Iglesias, C.* ; Schricker, G.* ; Haydn, O.* ; Kiechle, M.* ; Grill, S.W.* ; Heeren, R.* ; Knolle, P.A.* ; Wilhelm, O.* ; Höchst, B.*

Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.

Breast Cancer Res. 27:107 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Breast cancer, one of the most common cancers in women, is classified by the expression of hormone receptors and the growth factor receptor HER2, which is important for personalised tumour treatment with HER2-targeted therapies. Tumour biopsies are required for histopathological diagnosis of HER2 expression by breast cancer cells but are subject to sampling error. In this study, we present a method for identifying and analysing cancer-derived EVs from plasma for the detection of HER2 expression in breast cancer without the need for additional processing steps. We detected nano-sized particles through an optimised flow cytometry approach that allows for the identification of HER2-expressing EVs and quantification of their HER2 expression levels. In a clinical study of 115 breast cancer patients, this optimised flow cytometric analysis detected a range of 1.3 to 50 × 103 HER2+EVs per µl of plasma. The number of HER2+EVs did not correlate directly with tumour size, grade, or metastasis. However, computational integration of data from the quantification of HER2pos EVs per µl/plasma and their HER2 expression levels on a single EV basis allowed for the reliable identification of HER2 expression levels in tumours. Our results reveal the potential for analysing cancer-derived EVs from plasma for the diagnosis and personalised therapy in breast cancer patients.
Impact Factor
Scopus SNIP
Altmetric
5.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Biogenesis; Prognosis; Exosomes; Subtypes; Impact
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1465-5411
e-ISSN 1465-542X
Zeitschrift Breast Cancer Research
Quellenangaben Band: 27, Heft: 1, Seiten: , Artikelnummer: 107 Supplement: ,
Verlag BioMed Central
Verlagsort Campus, 4 Crinan St, London N1 9xw, England
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
Institute of Structural Biology (STB)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
Enabling and Novel Technologies
PSP-Element(e) G-501500-001
G-501501-001
G-503010-001
Förderungen Bundesministerium fr Bildung und Forschung
DOI 10.1186/s13058-025-02056-z
WOS ID 001510029500001
Scopus ID 105008111179
PubMed ID 40524202
Erfassungsdatum 2025-07-11
[➜Korrektur melden]